Vaccine efficacy against severe COVID-19 is so high, even for the Delta variant, that booster doses for the general population are "not appropriate" at this stage in the pandemic, an international group of scientists argued in a review published in The Lancet.
The review, which includes scientists from the World Health Organization (WHO) and two from the US Food and Drug Administration (FDA), who will leave the agency, comes even as the latter is currently reviewing evidence for booster doses for Americans; and many other countries including Israel, Italy, France and Russia who have already rolled out the third dose of COVID jabs.
It summarises the currently available evidence from randomised controlled trials and observational studies published in peer-reviewed journals and pre-print servers and asserts that the benefits of the first shots are clear.
It added that vaccination had 95 percent efficacy against severe disease both from the Delta variant and from the Alpha variant, and over 80 percent efficacy at protecting against any infection from these variants.
"Taken as a whole, the currently available studies do not provide credible evidence of substantially declining protection against severe disease, which is the primary goal of vaccination. Even if some gain can ultimately be obtained from boosting, it will not outweigh the benefits of providing initial protection to the unvaccinated," said lead author Ana-Maria Henao-Restrepo from the WHO.
Last week, Pascal Soriot, CEO of AstraZeneca, also said that a third dose of vaccines against COVID-19 may not be needed for everyone.
Writing in the Telegraph, he stated that the decision to jab the entire population must be based on "real world clinical effectiveness data, not simply antibody measurements".
The WHO has, meanwhile, called for an extension of a global moratorium on COVID-19 booster doses, with an aim to enable every country to vaccinate at least 40 percent of its population.
According to the WHO, globally 5.5 billion vaccine doses have been administered, but 80 percent have been administered in high- and upper-middle income countries.
WHO Director-General Tedros Adhanom Ghebreyesus reiterated that third doses may be necessary for the most at-risk populations, but for now, "we do not want to see widespread use of boosters for healthy people who are fully vaccinated".
"These high-stakes decisions should be based on robust evidence and international scientific discussion," adds co-author Soumya Swaminathan, WHO Chief Scientist.
(This story was published from a syndicated feed. Only the headline and picture has been edited by FIT.)
(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)